Abstract
Identification of novel and selective anticancer agents remains an important and challenging goal in pharmacological research. The indole nucleus, frequently encountered as a molecular fragment in natural products and pharmaceutically active compounds, was employed as the initial building block for the synthesis of a series of pyrazino[1,2- a]indoles 1a-k, variably substituted at the 6, 7, 8 and 9-positions. Compound 1e, bearing the methoxy group at the 8- position of the pyrazino[1,2-a]indole nucleus was identified as a novel potent antiproliferative agent against the human chronic myelogenous leukemia K562 cell line, but it was much less active against several other cancer cell lines. Comparison of positional isomers indicated that moving the methoxy group from the 8- to the 7- or 6-position, to furnish compounds 1f and 1g, respectively, yielded inactive compounds. The analysis of structure-activity relationships observed in the series of investigated compounds may represent the basis for the design of more active molecules.
Keywords: Pyrazino[1,2-a]indole, Human leukemia K562 cell line, Anticancer agents
Letters in Drug Design & Discovery
Title: Discovery of 8-methoxypyrazino[1,2-a]indole as a New Potent Antiproliferative Agent Against Human Leukemia K562 Cells. A Structure-Activity Relationship Study
Volume: 6 Issue: 4
Author(s): Romeo Romagnoli, Pier Giovanni Baraldi, Maria Dora Carrion, Olga Cruz-Lopez, Carlota Lopez Cara, Delia Preti, Mojgan Aghazadeh Tabrizi, Jan Balzarini, Ernest Hamel, Enrica Fabbri and Roberto Gambari
Affiliation:
Keywords: Pyrazino[1,2-a]indole, Human leukemia K562 cell line, Anticancer agents
Abstract: Identification of novel and selective anticancer agents remains an important and challenging goal in pharmacological research. The indole nucleus, frequently encountered as a molecular fragment in natural products and pharmaceutically active compounds, was employed as the initial building block for the synthesis of a series of pyrazino[1,2- a]indoles 1a-k, variably substituted at the 6, 7, 8 and 9-positions. Compound 1e, bearing the methoxy group at the 8- position of the pyrazino[1,2-a]indole nucleus was identified as a novel potent antiproliferative agent against the human chronic myelogenous leukemia K562 cell line, but it was much less active against several other cancer cell lines. Comparison of positional isomers indicated that moving the methoxy group from the 8- to the 7- or 6-position, to furnish compounds 1f and 1g, respectively, yielded inactive compounds. The analysis of structure-activity relationships observed in the series of investigated compounds may represent the basis for the design of more active molecules.
Export Options
About this article
Cite this article as:
Romagnoli Romeo, Baraldi Giovanni Pier, Carrion Dora Maria, Cruz-Lopez Olga, Cara Lopez Carlota, Preti Delia, Tabrizi Aghazadeh Mojgan, Balzarini Jan, Hamel Ernest, Fabbri Enrica and Gambari Roberto, Discovery of 8-methoxypyrazino[1,2-a]indole as a New Potent Antiproliferative Agent Against Human Leukemia K562 Cells. A Structure-Activity Relationship Study, Letters in Drug Design & Discovery 2009; 6 (4) . https://dx.doi.org/10.2174/157018009788452519
DOI https://dx.doi.org/10.2174/157018009788452519 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MiRNAs in Human Cancers: The Diagnostic and Therapeutic Implications
Current Pharmaceutical Design Pharmacogenetics of Non-small Cell Lung Cancer (NSCLC): Time to "Work it Out"?
Current Pharmaceutical Design Resistance to Radiotherapy and Targeted Molecular Therapies in Squamous Cell Carcinomas of the Head and Neck, Preclinical Data and New Approaches
Current Signal Transduction Therapy Heat Shock Protein 90 – a Potential Target in the Treatment of Human Acute Myelogenous Leukemia
Current Cancer Drug Targets The Significance of COX-2 and COX-2 Inhibitors in Liver Fibrosis and Liver Cancer
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents The Importance of Humanized Yeast to Better Understand the Role of Bcl-2 Family in Apoptosis: Finding of Novel Therapeutic Opportunities
Current Pharmaceutical Design Antiangiogenic Therapy
Current Pharmaceutical Design Using PET Studies of P-gp Function to Elucidate Mechanisms Underlying the Disposition of Drugs
Current Topics in Medicinal Chemistry Synthesis of New Cyanopyridine Scaffolds and their Biological Activities
Current Organic Synthesis Insights into Cellular Uptake of Nanoparticles
Current Drug Delivery Generating ‘Omic Knowledge’: The Role of Informatics in High Content Screening
Combinatorial Chemistry & High Throughput Screening Editorial [Hot Topic: Modulation, Absorption and Delivery of Xenobiotics: The Synergic Role of CYP450 and P-gp Activities (Guest Editor: Nicola Antonio Colabufo)]
Current Drug Metabolism Magnetic Nanoparticles for MRI of Brain Tumors
Current Pharmaceutical Biotechnology Development of Novel Therapeutic Drugs in Humans from Plant Antimicrobial Peptides
Current Protein & Peptide Science Multiscale Imaging of Nanoparticle Drug Delivery
Current Drug Targets Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain
CNS & Neurological Disorders - Drug Targets Mitochondria as Possible Pharmaceutical Targets for the Effects of Vitamin E and its Homologues in Oxidative Stress-Related Diseases
Current Pharmaceutical Design Evaluation of Dendrimer Safety and Efficacy through Cell Line Studies
Current Drug Targets Anticancer Drug Sensitivity Testing, a Historical Review and Future Perspectives
Current Drug Therapy The Correspondence Between Magnetic Resonance Images and the Clinical and Intraoperative Status of Patients with Spinal Tumors
Current Medical Imaging